#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes
International, ALL RAS cancers
Joined February 2020
- Tweets5K
- Following4.9K
- Followers4.2K
- Likes12.5K
Pinned Tweet
At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder.
Personalized: KRAS G12D, CRC, US trials
Results (in 4 minutes): 20 trials
go to KRASHUB.ORG
in beta - would love your feedback
abstract
asco.org/abstracts-presentat…
FYI:
G12V - 8 trials for CRC
G12R - 7 trials for CRC
KRAS Kickers retweeted
Mechanism wise there has got to be a bi-directional crosstalk between wild type RAS and PRMT5
First Daraxonrasib has greater ORR than Zoldonrasib per press release, and second:
“and partly because targeting PRMT5 may attenuate some of Rasonque’s toxicities”
KRAS Kickers retweeted
Placebo Controlled Randomized Trial: Memantine given w/Brain RT Improved Cognitive Outcomes & QOL 1/3 sciencedirect.com/science/ar…
KRAS Kickers retweeted
Today at #ESMO26: Zev Wainberg will present additional subgroup analyses from the phase 3 RASolute 302 study of daraxonrasib vs. chemotherapy in previously treated metastatic pancreatic adenocarcinoma. @MSKCancerCenter's @EileenMOReilly is the senior author.
📅 October 23 | 2:22 p.m. CEST
ALT A promotional graphic featuring headshots of Zev Wainberg and Eileen O'Reilly and the presentation title and date.
KRAS Kickers retweeted
AMPLIFY-7P randomised ph2
✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile
➡️curative intent & no recurrence <6mth #PDAC
✅T cell responses,primary endpt-ve
➡️benefit in ctDNA-ve& no rads?
➡️DFS @6mth benefit of 14% p=0.056
✅ph3 planned
@myESMO @OncoAlert #ESMO26
KRAS Kickers retweeted
Zev Wainberg presents subgroup analyses from phase 3 RASolute 302 study of #daraxonrasib in patients with previously treated metastatic #PDAC at #ESMO26 (part 1) #ESMOAmbassadors @myESMO
KRAS Kickers retweeted
AMPLIFY-7P ph 2 study: Seven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected PDAC)
#ESMO26 #ESMOAmbassadors
👉 Targeting lymph nodes to activate T-cells
👉T-cells response in 99% of pts
👉poor outcome in ctDNA pos pts
🧐promising data, specifically in pts with Tcell response
@myESMO
KRAS Kickers retweeted
#LBA82 subgroup analysis RASolute 302 #PDAC
➡️HR for OS across subtypes 0.32-0.46
➡️G12R 0.61 (0.29-1.30)
➡️RAS WT numbers small (3%) but still OS benefit!
🤔perhaps ORR and mPFS not as pronounced in these populations!
✅std second line treatment
@myESMO #ESMO26 @OncoAlert
KRAS Kickers retweeted
#ESMO26 🚀 RASolute 302 | Phase III
👥 500 pts | Previously treated mPDAC
💊 Daraxonrasib (RAS(ON) inhibitor) vs chemo
📈 OS: 13.2 vs 6.7 mo (HR 0.40)
🧬 OS benefit by RAS genotype:
🔹 G12D: HR 0.49
🔹 G12V: HR 0.32
🔹 G12R: HR 0.61
📊 PFS: HR 0.55 (BICR)
🎯 ORR: 32% vs 11%
💡 new SOC!
@OncoAlert
KRAS Kickers retweeted
Wow 🤩 #ESMO26
Plus 3 papers in @JCO_ASCO 💪
@myESMO @OncoAlert @Annals_Oncology @ESMO_Open @TheLancet @JAMA_current @TheLancetOncol @NEJM @Nature @NatureMedicine
KRAS Kickers retweeted
Coming up at #ESMO26: MSK gastrointestinal medical oncologist @EileenMOReilly will present the AMPLIFY-7P randomized phase 2 study comparing an mKRAS-specific immunotherapy with observation in patients with resected pancreatic ductal adenocarcinoma.
🗓️ Friday, October 23 | 2:32 p.m. CEST
KRAS Kickers retweeted
Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran.
Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
KRAS Kickers retweeted
📍Don’t miss the lecture @myESMO #ESMO26 “Drugging the undruggables: The next wave of targeted therapies” @OncoAlert @oncodaily Link -
cslide.ctimeetingtech.com/es…
Put @VivekSubbiah's #ESMO26 lecture on drugging the undruggables on your list. The pearl for fellows: KRAS G12C went from undruggable to approved by trapping the inactive GDP-bound state, and the next wave is going after the active RAS(ON) state instead.
KRAS Kickers retweeted
Joining #UpperGIHPB2026 in Bengaluru virtually for the keynote, with the latest data from #ESMO:
"Metastatic Pancreatic Cancer 2026: From Cytotoxicity to KRAS: Are We Finally Changing the Game?"
📅 Oct 31, 6:45 PM IST
Thanks @ApolloCancerCentres & Dr. Vishwanath S!
KRAS Kickers retweeted
How to start dermatologic prophylaxis before first dose, Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
We’re excited for ESMO2026, where we’ll share subgroup analyses from RASolute 302 and connect with colleagues across the oncology community.
Swipe through to see where you can find Revolution Medicines throughout the congress.
#ForMediaOnly
KRAS Kickers retweeted
Hitting KRAS G12D without the gut punch: Can immunotherapy make it last? dlvr.it/TW0Kf0
KRAS Kickers retweeted
Lung leading the way with all the fun new things.
Keep an eye on KRASCENDO1 and DELLPHi-305; these will have implications for G12C and high grade NET GI patients…
@OncoAlert @TheGutOncLab
#ESMO2026
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
